Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs. According to a Department of ...

Learn the benefits and risks of options and how to start trading options Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Samantha (Sam) Silberstein, CFP®, CSLP®, ...

Digital health company Happify has signed a partnership with another biopharma company, joining forces with Biogen on a toolkit to help people with multiple sclerosis manage their illness. The digital ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, ...

There has been much discussion and debate recently about the scientific considerations related to 'follow-on' protein products (including peptides; Box 1, Note 1). These are protein products that are ...

Our understanding of the pathogenesis of multiple sclerosis (MS) has widened beyond the traditional view of a chronic autoinflammatory disease of the CNS white matter, which is mediated by ...

Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to ...

Medicare covers various aspects of multiple sclerosis (MS) treatment, including medications, therapy, hospital stays, and medical equipment, but the specific coverage depends on the Medicare plan.

In this article, we will look at the 10 Best Performing Pharma Stocks in 2025. On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss ...